drugset / Trial / NCT05761717
Clinical Study of mRNA Vaccine in Patients With Liver Cancer After Operation
NaSequentialOpen-labelTreatment
Summary
This is an open, one-arm study to evaluate the safety and efficacy of mRNA personalized tumor vaccine (tumor vaccine) encoding neonatal antigen in combination with Sintilimab injection for adjuvant prevention of postoperative recurrence of hepatocellular carcinoma.
Timeline
- Start
- 2023-04-20
- Primary completion
- 2025-03-12
- Completion
- 2025-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neoantigen mRNA Personalised Cancer vaccine | Messenger RNA (mRNA) | 50 ug | Subcutaneous |
| Subject | Neoantigen mRNA Personalised Cancer vaccine | Messenger RNA (mRNA) | 100 ug | Subcutaneous |
| Subject | Neoantigen mRNA Personalised Cancer vaccine | Messenger RNA (mRNA) | 150 ug | Subcutaneous |
| Background | Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection | Unknown | — | — |